Pedro Nazareth Aguiar (Pedro Aguiar Júnior, Pedro Nazareth Aguiar Junior, Pedro N Aguiar)

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 9

Top Topics

Small Cell Lung Cancer

Positive Breast Cancer

Top Venues

Einstein (Sao Paulo, Brazil)

Sao Paulo medical journal = Revista paulista de medicina

JCO global oncology

Future oncology (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Bruna Bianca Lopes David, Pedro Nazareth Aguiar, Matheus Costa E Silva, Rodrigo Dienstmann, Carlos Gil Ferreira, Cesar Serrano
Cost Evaluation Analysis of Genetic Testing and Tailored Adjuvant Imatinib in Patients With Resected High-Risk GI Stromal Tumors: The Brazilian Perspective. JCO global oncology 9 (2023)
Pedro Nazareth Aguiar, Silvio Matsas, Rodrigo Dienstmann, Carlos Gil Ferreira
Challenges and opportunities in building a health economic framework for personalized medicine in oncology. Personalized medicine (2023)
Pedro Nazareth Aguiar, Mirella Stival, Marcos Aurélio Fonseca Magalhães Filho, Auro Del Giglio
Physical Examination in Medical Oncology Guiding the Development of a Protocol for Teleoncology Care in a Public Health Care Oncology Service. JCO clinical cancer informatics 7 (2023)
Geane Tomaídes Henriques, Cleide Barbieri de Souza, Pedro Nazareth Aguiar
Predictive genetic biomarkers in immune checkpoint inhibitors for non-small-cell lung cancer. Immunotherapy 14 (4) (2022)
Marcos Aurélio Fonseca Magalhães Filho, Pedro Nazareth Aguiar, Milena Brachmans Mascarenhas Neves, Gilberto de Lima Lopes, Auro Del Giglio
Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer. Einstein (Sao Paulo, Brazil) 20 (2022)
Daniela Pezzutti Domigues Armentano, Mariana Ribeiro Monteiro, Pedro Nazareth Aguiar, Jessica Sayuri Tsukamoto, Raquel Baptista Pio, Renata Eliane DE Ávila, Raphael Leonardo Cunha de Araujo, Pedro Luiz Serrano UsÓn Junior
Laboratory variables as predictors of progression in gastroenteropancreatic neuroendocrine tumors in different lines of antineoplastic treatments. Einstein (Sao Paulo, Brazil) 20 (2022)
Luiz Henrique Araujo, Clarissa Seródio Baldotto, Mariana R Monteiro, Pedro Nazareth Aguiar, Maria Clara Andrade, Cecília L Longo, Mayara Batista, Raphaela Lima, Débora Azevedo, Natalia Carvalho, Perla Andrade, Mauro Zukin, Nelson Teich
Patient-centered outcomes in non-small-cell lung cancer: a real-world perspective. Future oncology (London, England) 17 (14) (2021)
Pedro Nazareth Aguiar, Carmelia Maria Noia Barreto, Felipe Santa Rosa Roitberg, Gilberto de Lima Lopes, Auro Del Giglio
Potential life years not saved due to lack of access to anti-EGFR tyrosine kinase inhibitors for lung cancer treatment in the Brazilian public healthcare system: Budget impact and strategies to improve access. A pharmacoeconomic study. Sao Paulo medical journal = Revista paulista de medicina 137 (6) (2020)
Pedro Nazareth Aguiar, Pui San Tan, Sarah Simko, Carmelia Maria Noia Barreto, Bárbara de Souza Gutierres, Auro Del Giglio, Gilberto de Lima Lopes
Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer. Einstein (Sao Paulo, Brazil) 17 (2) (2019)